Previous 10 | Next 10 |
7 Penny Stocks For Your Monday Morning Watchlist With another week upon us, which penny stocks are investors watching right now? Well, after a week of some wild trading, there are plenty of penny stocks showing bullish potential as we head into the first week of July. And in order t...
Intellia Therapeutics (NTLA) +58%. after releasing interim data from a phase 1 trial of a CRISPR candidate.Marin Software Incorporated (MRIN) +38%.ReShape Lifesciences (RSLS) +34%.Anavex Life Sciences (AVXL) +24% after after ANAVEX2-73 improved endpoints in Phase 2 Parkinson’s dis...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning! Let’s get ready for trading to start off strong this week with a look at the biggest pre-market stock movers for Monday! Source: Eric Urquhart/Shutterstock.com We’re seeing a lot of medic...
Arbutus Biopharma (ABUS) jumps 18.7% premarket after announcing AB-729 and AB-836 data in chronic hepatitis B virus ((HBV)) infection at the EASL International Liver Congress. AB-729 continues to demonstrate robust mean HBsAg reduction across all doses and dosing...
AB-729, dosed at 60 mg every 8 weeks, achieved a mean HBsAg decline of -1.87 log10 IU/mL at week 44, comparable to 60 mg dosed every 4 weeks AB-729 resulted in HBsAg declines below 100 IU/ml in 75% of treated subjects, and increased HBV-specific immune responses in 3/5 evaluable s...
Conference Call and Webcast to discuss the new data being presented at EASL scheduled for 8:00 AM ET, Monday, June 28, 2021 WARMINSTER, Pa., June 02, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focus...
James River Group Holdings (JRVR) -23% after stock offering and Q1 earnings release.Fastly (FSLY) -19% on Q1 earnings release.Regional Health Properties (RHE) -15%.Rocket Companies (RKT) -13% on Q1 earnings release.Etsy (ETSY) -11% on Q1 earnings releas...
The following slide deck was published by Arbutus Biopharma Corporation in conjunction with their 2021 Q1 earnings call. For further details see: Arbutus Biopharma Corporation 2021 Q1 - Results - Earnings Call Presentation
Image source: The Motley Fool. Arbutus Biopharma (NASDAQ: ABUS) Q1 2021 Earnings Call May 05, 2021 , 8:45 a.m. ET Operator Continue reading For further details see: Arbutus Biopharma (ABUS) Q1 2021 Earnings Call Transcript
Arbutus Biopharma Corporation (ABUS) Q1 2021 Earnings Conference Call May 05, 2021 08:45 AM ET Company Participants Pam Murphy - Investor Relations Bill Collier - President & Chief Executive Officer Dave Hastings - Chief Financial Officer Gaston Picchio - Chief Development Officer Mike So...
News, Short Squeeze, Breakout and More Instantly...
Arbutus Biopharma Corporation Company Name:
ABUS Stock Symbol:
NASDAQ Market:
Arbutus Biopharma Corporation Website:
WARMINSTER, Pa., July 18, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that it ...
Data highlighted in oral presentation at the European Association for the Study of the Liver (EASL) Congress WARMISTER, Pa., June 06, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmac...
In t he HBV003 trial, 67% of participants had HBsAg <10 IU/mL and 19% of participants had undetectable HBsAg when assessed for NUC discontinuation (end of treatment) or later, and 76% of participants were eligible for nucleos(t)ide analogue (NUC) therapy discontinuation. In the...